(4R,5S)-(+)-4-甲基-5-苯基-2-恶唑啉酮 | 77943-39-6

• 物质功能分类: 生物化工 - 多肽
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (4R,5S)-(+)-4-甲基-5-苯基-2-恶唑啉酮
• 中文别名: (4R,5s)-(+)-4-甲基-5-苯基-2-噁唑烷酮；(4R,5S)-4-甲基-5-苯基-2-噁唑啉酮
• 英文名称: 4-methyl-5-phenyloxazolidin-2-one
• 英文别名: (4R,5S)-(+)-4-methyl-5-phenyl-2-oxazolidinone；(4R,5S)-4-methyl-5-phenyl-1,3-oxazolidin-2-one
• CAS: 77943-39-6
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: PPIBJOQGAJBQDF-VXNVDRBHSA-N

物化性质

• 熔点：
  121-123 °C(lit.)
• 沸点：
  309.12°C (rough estimate)
• 密度：
  1.1607 (rough estimate)
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）
• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  N
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储于阴凉干燥处。

SDS

Name:	(4R 5S)-(+)-4-Methyl-5-phenyl-2-oxazolidinone 99% Material Safety Data Sheet
Synonym:	None Known
CAS:	77943-39-6

Section 1 - Chemical Product MSDS Name:(4R 5S)-(+)-4-Methyl-5-phenyl-2-oxazolidinone 99% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
77943-39-6	(4R,5S)-(+)-4-Methyl-5-phenyl-2-oxazol	99%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 77943-39-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 106 - 109 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H11NO2
Molecular Weight: 177.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 77943-39-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4R,5S)-(+)-4-Methyl-5-phenyl-2-oxazolidinone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 77943-39-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 77943-39-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 77943-39-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：该手性助剂适用于与酰基卤（1,2,3）及羧酸的缩合反应（4,5,6）。

反应信息

• 作为反应物：
  描述：

  (4R,5S)-(+)-4-甲基-5-苯基-2-恶唑啉酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 麻黄素
  参考文献：
  名称：

  Synthesis of Three Novel Fluorine-18 Labeled Analogues of l-Deprenyl for Positron Emission Tomography (PET) studies of Monoamine Oxidase B (MAO-B)

  摘要：

  The aim in this project was to synthesize and to study fluorine-18 labeled analogues of L-deprenyl which bind selectively to the enzyme monoamine oxidase B (MAO-B). Three fluorinated L-deprenyl analogues have been generated in multistep organic syntheses. The most promising fluorine-18 compound N-[(2S)-1-[F-18]fluoro-3-phenylpropan-2-yl]-N-methylprop-2-yn-1-amine (4c) was synthesized by a one-step fluorine-18 nucleophilic substitution reaction. Autoradiography on human brain tissue sections demonstrated specific binding for compound 4c to brain regions known to have a high content of MAO-B. In addition, the corresponding nonradioactive fluorine-19 compound (13) inhibited recombinant human MAO-B with an IC50 of 170.5 +/- 29 n/v1 but did not inhibit recombinant human MAO-A (IC50 > 2000 nM), demonstrating its specificity. Biodistribution of 4c in mice showed high initial brain uptake leveling at 5.4 +/- 0.04%ID/g after 2 min post injection. In conclusion, compound 4c is a specific inhibitor of MAO-B with high initial brain uptake in mice and is, therefore, a candidate for further investigation in PET.

  DOI：

  10.1021/jm200710b
• 作为产物：
  描述：

  DL-苯丙醇胺盐酸盐 在 氢氧化钾 、 sodium hydroxide 作用下， 反应 6.67h， 生成 (4R,5S)-(+)-4-甲基-5-苯基-2-恶唑啉酮
  参考文献：
  名称：

  Erythro-directive reduction of .alpha.-substituted alkanones by means of hydrosilanes in acidic media

  摘要：

  DOI：

  10.1021/jo00258a004
• 作为试剂：
  描述：

  (4R,5S)-(+)-4-甲基-5-苯基-2-恶唑啉酮 、 4,4,4-三氟丁酰氯 在 (4R,5S)-(+)-4-甲基-5-苯基-2-恶唑啉酮 作用下， 以86的产率得到(4R,5S)-3-(1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazolidinone
  参考文献：
  名称：

  A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof

  摘要：

  公开号：

  EP0489548B1

文献信息

• Synthetic studies in the lysocellin family of polyether antibiotics. The total synthesis of ferensimycin B
  作者：David A. Evans、Richard P. Polniaszek、Keith M. DeVries、Denise E. Guinn、David J. Mathre

  DOI：10.1021/ja00020a025

  日期：1991.9

  A convergent asymmetric synthesis of the polyether antibiotic ferensimycin B has been completed. Chiral enolate bond constructions were employed to establish seven of the 16 stereocenters of the subunits 35 and 52, which comprise the C& and CI&3 portions of ferensimycin B. The stereogenic centers at C3, C4, Cg, Clo, CI6, C,,, and CIS were incorporated through internal asymmetric induction, while those

  聚醚抗生素ferensimycin B的收敛不对称合成已经完成。手性烯醇键结构用于建立亚基 35 和 52 的 16 个立体中心中的 7 个，这些立体中心包括费伦霉素 B 的 C& 和 CI&3 部分。 C3、C4、Cg、Clo、CI6、C、、和CIS 通过内部不对称诱导合并，而在 Cm 和 C1l 的那些是通过使用不对称环氧化方法建立的。在这种转化中，采用钒催化的双高烯丙醇内环氧化反应将手性从 C13 传递到 CI6 含氧立体中心。在没有保护基团的中间体上的最终羟醛加成反应将片段 52 和 35 结合在一起，以提供合成的费伦霉素 B，发现其绝对构型为
• [EN] CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP<br/>[FR] LIEURS DE CONJUGAISON CONTENANT UN GROUPE 2,3-DIAMINOSUCCINYLE
  申请人：HANGZHOU DAC BIOTECH CO LTD

  公开号：WO2020073345A1

  公开（公告）日：2020-04-16

  Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

  提供的是将细胞毒性药物/分子与含有双联接剂（双联接剂）的细胞结合分子结合的共轭物。它还涉及将细胞毒性药物/分子与双联接剂的细胞结合分子结合的制备，特别是当药物具有氨基，羟基，二氨基，氨基-羟基，二羟基，羧基，双肼，醛基和硫醇等功能基团以特定方式与双联接剂结合时，以及这些共轭物的治疗用途。
• Total synthesis of the macrolide antibiotic cytovaricin
  作者：David A. Evans、Stephen W. Kaldor、Todd K. Jones、Jon Clardy、Thomas J. Stout

  DOI：10.1021/ja00175a038

  日期：1990.9

  A convergent asymmetric synthesis of the antinoeplastic macrolide antibiotic cytovaricin has been achieved through the synthesis and coupling of the illustrated spiroketal and polyol glycoside subunits. All absolute steroechemical relationships within the target structure were ultimately controlled by the use of asymmetric aldol, alkylation, or epoxidation methodology. Union of the two subnits was

  通过图示的螺缩酮和多元醇糖苷亚基的合成和偶联，已经实现了抗肿瘤大环内酯类抗生素细胞病毒素的收敛不对称合成。目标结构内的所有绝对立体化学关系最终都通过使用不对称羟醛、烷基化或环氧化方法来控制。两个亚硝基的结合是通过 Julia-Lythgoe 反式烯化完成的，提供了对合适的大环内酯化底物的直接访问
• 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
  申请人：ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．ＨＡＮＧＺＨＯＵ ＤＡＣ ＢＩＯＴＥＣＨ ＣＯ．，ＬＴＤ．

  公开号：JP2021073185A

  公开（公告）日：2021-05-13

  【課題】連結体の製造方法及び均一な共役体の製造におけるそのような連結体の使用方法、並びに癌、感染症、及び自己免疫疾患の治療における共役体の適用方法に関する。【解決手段】細胞結合分子上のチオールの対に特異的に架橋連結することにより、連結体あたり２以上の化合物／細胞毒性剤を細胞結合分子と共役させるための、２，３−ジ置換コハク酸基又は２−モノ置換若しくは２，３−ジ置換フマル酸又はマレイン酸（トランス（Ｅ）−又はシス（Ｚ）−ブテン二酸）基を含む新規な連結体。上記連結体は下記一般式で例示される。【選択図】なし

  在这个文本中，描述了一种用于制造连接体和制造均一的共轭体的方法，以及在癌症、感染症和自身免疫性疾病治疗中应用共轭体的方法。通过特异性地交联连接到细胞结合分子上的巯基对，使得每个连接体能够与两个或两个以上的化合物/细胞毒性剂共轭，其中连接体包含2,3-二取代琥珀酸基或2-单取代或2,3-二取代富马酸基或马来酸基（反式（E）-或顺式（Z）-丁烯二酸）基。这些连接体可以用以下通用式来表示。【选择图】无
• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2013134562A1

  公开（公告）日：2013-09-12

  The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

  本发明涉及的化合物属于式(I)及其药学上可接受的盐，可用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式(I)化合物的治疗有效量或其药学上可接受的盐的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予选择性PPARα拮抗剂的治疗有效量。本发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。本发明还涉及一种预防急性和慢性骨髓性白血病以及其他癌症发作和/或复发的方法，包括给予选择性PPARα拮抗剂的治疗有效量。